Company attributes
Venture Capital Firm attributes
Other attributes
Founded in 2009, Kurma Partners is a venture capital firm based in Paris, France. Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, from pre-seed to growth capital.
Kurma Partners manages the Kurma Biofund I, II and III funds and the Kurma Diagnostics fund and is involved in the financing of therapeutic and medical innovations in Europe, particularly through their links with medical institutes, research institutes and hospitals.
Kurma Partners' investments include FeetMe, Tacalyx, Ermium Therapeutics, Pharvaris, AM Pharma, DNA Script and Asarina Pharma.
Their exited investments include Minoryx Therapeutics, STAT-Dx, Alizé Pharma, Orphazyme, Asarina Pharma and Safe Orthopaedics.
Kurma Partners has raised a total of €291 million across 4 funds, their latest being Kurma Biofund III. This fund was announced on December 17, 2018 and raised a total of €150 million. They announced their Kurma Diagnostics Fund on May 26, 2015 with a raised total of €35 million. Their Kurma Biofund II on June 20, 2013 with a raised total of €55 million. And they announced their Kurma Biofund I on January 1, 2010 with a raised total of €51 million.
